Month: March 2022

For several years we have been hearing about the potential of Artificial Intelligence (AI) to improve traditional drug discovery and development. In the last two years, clinical trials have begun. The UK’s Exscientia made headlines last April by announcing the start of a Phase 1 clinical trial for a drug it designed using AI for an established protein target. Recursion Pharmaceuticals in Utah uses AI to find new uses for the drugs owned by other companies. Insilico Medicine has now announced the crucial next step: the start of the world’s first Phase 1 clinical trial of a drug developed from...

“Not proper science” The field of longevity medicine is coming alive. Until the last few years, the project of halting and reversing aging was not seen as “proper science”, and not a fit use for public funds. Aging was seen as an inevitable and permanent part of the human condition. It was not a disease, but a vulnerability to disease which grows over time, and cannot be redressed. People who argued the contrary were viewed by the medical establishment as entertaining mavericks at best, disreputable charlatans at worst. The sneering has not entirely disappeared, but today there is significant investment...